Sponsored By

Drop the 'Remote', It's Just Patient Monitoring

Dr. Jim Mault, BioIntelliSense CEO, breaks down the rise of remote patient monitoring and explains why it’s time to drop the term for this episode of Let's Talk Medtech.

Omar Ford

October 6, 2022

1 Min Read
IMG_2022-10-6-125920.jpg
Image Courtesy of BioIntellisense

 

Remote patient monitoring has been around for some years now, but the pandemic helped catapult the sector to the forefront.

The forecast for the remote patient monitoring market shows that it’s expected to reach $175 billion by 2027 from $53.6 billion in 2022 during the forecast period, according to a report from Markets and Markets.

It’s a market that BioIntelliSense is making an impact in. The firm has developed the BioButton, multi-parameter wearable device and advanced data services for continuous vital sign monitoring.

Jim Mault, MD, BioIntelliSense CEO and founder spoke about the rise of the market and why remote patient monitoring is a misnomer in this all-new episode of Let’s Talk Medtech.

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like